Effect of atorvastatin pretreatment on percutaneous coronary intervention-related inflammation and myocardial injury

Objective:To explore the effect of atorvastatin pretreatment on percutaneous coronary intervention(PCI)-related inflammation and myocardial injury.Methods:One hundred and three patients with coronary heart diseases undergoing PCI were randomized into control group(n=30),low-dose pretreatment group(n=36) and high-dose pretreatment group(n=37).They were given 0,20 and 40 mg atorvastatin tablet for 1 to 3 days before PCI,respectively.All patients took 20 mg atorvastatin every night after PCI.The neutrocyte count,the levels of high sensitivity C reactive protein(hs-CRP) and myeloperoxidase(MPO) were determined before and after PCI,and the level of cardiotroponin I(cTnI) was determined after PCI.The incidence of peri-procedural myocardial infarction was recorded.Results: The degree of MPO elevation in high-dose pretreatment group was significantly less than that of control group(P0.05),but there was no statistically significant difference between the low-dose pretreatment group and control group(P0.05).The changes of hs-CRP level and neutrocyte count were not significant before and after PCI in 3 groups(P0.05).Incidence of peri-procedural myocardial infarction was lowest in the high-dose pretreatment group.However,there was no significant difference among the 3 groups.Conculsion: Pretreatment with atorvastatin 40 mg for patients undergoing PCI for 1 to 3 days can inhibit PCI-related inflammation and may have a protective effect against myocardial injury.